Introduction
============

Alzheimer's disease (AD), also known as Senile Dementia, is a most common age-related neurodegenerative disorder. More than 11 million people per year are estimated to suffer from this disease by 2050, leading to higher cost as well as more burdens on public health and society ([@B3], [@B4]). Featured by progressive memory loss and cognitive dysfunction, AD induces the loss of motor functions and personality changes, and eventually leads to death. Histopathologically, AD is mainly characterized by extracellular senile plaques (SPs) and intracellular neurofibrillary tangles (NFTs), which results in the loss of neurons and synapses and finally causes gross atrophy of the brain. NFTs are formed by the regulation of the abnormally hyperphosphorylated and glycosylated microtubule-related tau protein, whereas SPs are associated with the aggregation and deposition of amyloid β peptides (Aβ) ([@B74]).

Aβ accumulation is considered to be the distinct morphological hallmark of early onset of AD and it is also proposed to be an activator to induce the sequential lesion events induced by the aggregation of P-Tau. Therefore, Aβ is predicted to be the most potentially efficient target of the drug therapies ([@B57]). Here, this review will focus on this peptide with the aspects of its biogenesis, regulations, as well as degradation and clearance to elucidate the potential significance of these processes for the clinic treatment of AD.

The A**β** Biogenesis, Toxicity, Production, and Clearance
==========================================================

The Biogenesis of A**β**
------------------------

The factors involved in the pathogenesis of AD have been intensely investigated, however, the mechanisms governing this disease are not fully understood and remain debated. One prevailing proposal is the amyloid cascade hypothesis positing Aβ as the initiator of subsequent events that leads to AD (**Figure [1A](#F1){ref-type="fig"}**) ([@B43]): Aβ peptides spontaneously aggregate and deposit into soluble oligomers, fibrils and SPs, which then induces oxidative injury, microglial and astrocytic activity as well as alters kinase/phosphatase activity, eventually leading to the neuronal death. Howerver, whether Aβ acts on tau aggregation is still debated ([@B79]).

![**(A)** The mechanism of Aβ toxicity. Accumulating Aβ will initially results in Aβ oligomerization, gradually deposits as the forms of fibrils and senile plaques. Furthermore, Aβ aggregation alters the kinase/phosphatase activity that leads to the Tau protein hyperphosphorylated, which causes the formation of neurofibrillary tangles (NFTs), and eventual synaptic and neuronal dysfunction and AD. **(B)** The proteolytic processing of the amyloid precursor protein (APP) and Aβ biogenesis. APP is a transmembrane glycoprotein with a large luminal domain and a short cytoplasmic domain, and it is processed through amyloidogenic or non-amyloidogenic pathway. The amyloidogenic pathway is the process of Aβ biogenesis: APP is firstly cleaved by β-secretase, producing soluble β-APP fragments (sAPPβ) and C-terminal β fragment (CTFβ, C99), and C99 is further cleaved by γ-secretase, generating APP intracellular domain (AICD) and Aβ. The non-amyloidogenic pathway is an innate way to prevent the generation of Aβ, as APP is firstly recognized by α-secretase within Aβ domain, generating soluble α-APP fragments (sAPPα) and C-terminal fragment α (CTFα, C83), C83 is then cleaved by γ-secretase, producing non-toxic P3 and AICD fragments.](fphar-06-00221-g001){#F1}

Aβ is a small protein composed of 39--43 amino acids with a variety of biophysical states. There are two major isoforms of Aβ, soluble Aβ~40~, and insoluble Aβ~42~, and the latter peptide showing higher percentage concentration in AD patients is more prone to aggregate ([@B13]; [@B39]; [@B58]). In a physiological condition, more than 90% of Aβ is in the form of Aβ~40~ while less than 5% is generated as the longer form of Aβ~42~.

Aβ is derived by proteolysis of an evolutionary conserved large transmembrane amyloid precursor protein (APP) through cleavage of β-secretase followed by γ-secretase. Mutations in the gene encoding APP are the main causes of familial AD (FAD; [@B19]; [@B37]). APP can also be processed by α-secretase via non-amyloidogenic pathways to produce non-toxic fragments, which is thought to antagonize Aβ generation (**Figure [1B](#F1){ref-type="fig"}**; [@B35]; [@B88]).

Most of intracellular Aβ normally distribute in the neuronal cytosol, but it is also colocalized with different organelles dependent on where APP, β- and γ-secretase reside. In particular, it has been reported to be produced in the secretory pathway related organelles including endoplasmic reticulum (ER), medial Golgi saccules as well as trans-Golgi network ([@B46]; [@B40]). It has also been found to be correlated with the endocytic endosomes/lysosomes and autophagic vacuoles ([@B62]; [@B112]). Besides, Aβ also resides in mitochondria ([@B78]).

Toxicity of A**β**
------------------

The physiological role of Aβ is still unknown, but it indeed exists throughout life in healthy individuals. One possible function is to inhibit the activity of γ-secretase in a negative feedback way ([@B53]).

Aβ aggregation is considered to be the primary reason for the neurotoxicity in the classic view, and Aβ oligomers are the most neurotoxic form ([@B102]). Three "developed-stimulators" may facilitate the aggregation process. The absolute levels of Aβ~42~ increased by production via APP processing, the ratio of Aβ~42~ to Aβ~40~ elevated due to the decreased level of Aβ~40~ or the soluble oligomeric Aβ ([@B36]; [@B103]). These potential stimulators further promote the accumulation and deposition of Aβ to develop into SPs, which eventually contributes to AD pathology. Moreover, Aβ-induced apoptosis through interaction with cell surface receptors and proteins is also thought to dedicate to the dysfunction of neuronal system ([@B93]; [@B114]).

The aggregation of Aβ might also promote free radicals such as reactive oxidative species (ROS) to react rapidly with several moieties of proteins and lipids, whose structures or functions are then altered to potential "toxic" oxidized proteins and peroxided lipids. Protein oxidation may cause harm to the membrane integrity or damage the sensitivity to oxidative modification of the enzymes such as glutamine synthetase (GS) and creatine kinase (CK), which are critical to neuronal function ([@B2]; [@B110]). Lipids peroxidation usually causes the toxic product such as 4-hydroxy-2-nonenal (HNE) and 2-propenal (acrolein) that migrates to different parts of the neurons to cause multiple deleterious alterations of cellular function. It includes loss of Ca^2+^ homoeostasis, inhibition of ion-motive ATPases and glial cell Na^+^-dependent glutamate and disruption of signaling pathways, all of which are associated with neuronal death ([@B73]; [@B100]; [@B32]). Aβ-induced oxidative stress has also been reported to cause the DNA oxidation, leading to DNA damage ([@B100]).

Continuous Aβ aggregation or sustained elevation of Aβ would cause a chronic response of the innate immune system by activating microglia through some immunological receptors such as Toll-like Receptors 2 (TLR2), TLR4, TLR6, their co-receptors CD14, CD36, and CD47, which can probably destroy functional neurons by direct phagocytosis ([@B105]; [@B82]; [@B70]). Besides, it also results in inflammatory response, concomitantly releasing a lot of inflammation related mediators including complement factors, eicosanoids, chemokines, and proinflammatory cytokines, which can impair microglial clearance of Aβ and the neuronal debris and increase microglia-mediated neuronal death and loss of neuronal synapses, contributing greatly to AD pathogenesis. Aβ deposition also induces tau pathology by promoting the intraneuronal formation of NFTs which consist of hyperphosphorylated tau proteins. It influences the late-stage of AD pathogenesis. The process is probably mediated by the microglia-driven neuroinflammatory response or by indirectly regulating kinase/phosphatase activity ([@B49]).

In addition, Aβ precursor APP accumulation at mitochondria membrane can cause mitochondrial dysfunction by blocking the translocation of other mitochondrial inner molecules/proteins and disrupting the electron-transport chain (ETC; [@B5]; [@B25]), which may in turn increase excessive Aβ generation to result in more toxicity. Excessive Aβ can also increase mitochondrial ROS production to induce mitochondrial fragmentation by activating mitochondrial fission proteins Drp1 and Fis1 ([@B8]). Aβ localized in mitochondria can bind to two pro-apoptotic factors including Aβ-binding alcohol dehydrogenase (ABAD) and cyclophin D (CypD), consequently increasing neurodegenerative cell death that may be toxic to neurons ([@B72]; [@B23]). Hence, there may be a vicious feedback loop between increased Aβ production and mitochondria dysfunction.

Regulations of A**β** Production and Clearance
----------------------------------------------

Because of the key role of Aβ in AD pathogenesis, it has been well accepted that reducing Aβ production or enhancing Aβ clearance may be a putative way to inhibit the cascade of Aβ-induced pathological events.

Aβ biogenesis is tightly correlated with APP metabolism, including processing and trafficking. There are three isoforms of APP, APP695, APP751, and APP770 ([@B37]). APP695 lacking the Kunitz-type protease inhibitor (KPI) domain is predominantly expressed in neurons while the other two isoforms are distributed in most tissues ([@B56]; [@B86]). Some evidence show that APP751 and APP770 up-expression in brains are primarily associated to Aβ deposition ([@B76]; [@B12]). APP processing is mainly regulated by α, β, and γ-secretases (**Table [1A](#T1A){ref-type="table"}**). Alpha-secretase plays an essential role in precluding the generation of intact Aβ on account of the cleavage site within the Aβ domain. As a membrane-bound endoprotease, α-secretase usually cleaves APP at plasma membrane ([@B92]). Several members of the [a]{.ul} Disintegrin [a]{.ul}nd [m]{.ul}etalloproteinase (ADAM) family listed in **Table [1A](#T1A){ref-type="table"}** have been reported to possess α-secretase activity, which is responsible for APP processing ([@B61]; [@B45]; [@B94]; [@B59]). β- and γ-secretases are devoted to Aβ production via amylodogenic pathway (**Figure [1B](#F1){ref-type="fig"}**). Beta-site APP cleaving enzyme 1 (BACE1) and BACE2 are the β-secretases while γ-secretase is complex and composed of presenilins (PSEN1 or PSEN2), Nicastrin, Presenilin enhancer 2 (PEN2), and anterior pharynx defective 1 (APH-1; [@B24]). Substantial evidence has shown that manipulation of these secretases could perturb the generation of Aβ. For example, with the α-cleavage abolished in ADAM17-deficient cells affectd Aβ generation ([@B14]). Knock-out of BACE1 in mice completely depleted neuronal Aβ secretion ([@B15]). Mutations of PSEN1 and PSEN2 affected APP cleavage, thereby altering Aβ production ([@B104]). Moreover, regulators related with these secratase, such as the γ-secretase activating protein (GSAP) and CD147, are also likely to be involved in the generation of Aβ ([@B113]; [@B47]).

###### 

Member proteins of three secretases.

  Secretase     Members in mammals
  ------------- -------------------------------------------------
  α-secretase   ADAM9, ADAM10, ADAM12, ADAM17, ADAM19, and MDC9
  β-secretase   BACE1 and BACE2
  γ-secretase   PSEN1, PSEN2, nicastrin, APH-1, and PEN-2

Like other type I transmembrane proteins, APP is synthesized and translocated into ER followed by matured in the Golgi apparatus where APP is mainly concentrated in neurons at the steady state ([@B46]; [@B108]; [@B40]; [@B18]). And then APP would traffic through the constitutive secretory pathway. Once reaching the cell surface, it is either cleaved by α-secretase to produce sAPPα ([@B92]) or rapidly re-internalized by recognition of a "YENPTY" motif and subsequently recycled back to the cell surface by the recycling compartments or delivered to the lysosome for degradation through the endosomal--lysosomal systems ([@B38]; [@B18]). Generally, promoting APP delivery or inhibiting APP internalization from the cell surface favors the non-amyloidogenic processing, thereafter antagonizing the generation of Aβ. Elevating retention of APP in acidic compartments such as endosomes greatly adds the chances for amyloidogenic processing and consequent Aβ production. Mutations within the "YENPTY" internalization motif have been addressed to block APP internalization and consequently decrease Aβ generation ([@B85]). In contrast, mutation within extracellular KPI domain existing in APP751 and APP770 that assists APP sorting to plasma membrane causes APP retention in the ER, thereby elevating the Aβ production ([@B10]). Synaptic transmission indicated to accelerate APP endocytosis has also been shown to result in increasing the level of secreted Aβ ([@B20]). Some general modulators that could regulate APP trafficking, such as dynamin I ([@B16]), the RAB GTPase family including RAB1B, RAB6, RAB8, and RAB11 ([@B50]; [@B29]; [@B75]; [@B97]; [@B99]), and the SNX family including SNX17 and SNX33 ([@B64]; [@B91]), have also been found to be associated with Aβ generation. In addition, factors that function in the trafficking of the three secretases may also change the production of Aβ by affecting APP processing ([@B101]; [@B106]; [@B11]). The G-protein-coupled receptor protein GPR3, which is responsible for the cell surface localization of matured γ-secretase, stimulates Aβ production when it is overexpression ([@B96]).

Proteolytic degradation is thought to take a large part of responsibility in preventing Aβ aggregation or deposition into plaques. The enzymes or proteases in proteolytic degradation play important roles by cleaving Aβ into shorter soluble fragments without neurotoxic effect. The proteases including cathepsin B (CatB), cathepsin D (CatD), Gelatinase A, serine protease factor Xia (FXIa), matrix metalloprotein-9 (MMP-9), neprilysin (NEP), presequence protease (Prep) and the α~2~M complex are involved in Aβ clearance ([@B90]; [@B109]; [@B42]; [@B17]; [@B52]; [@B77]; [@B60]), while enzymes such as angiotensin-converting enzyme (ACE), endothelin-converting enzyme (ECE), insulin-degrading enzyme (IDE), and uPT and tPA have been found to be involved in the degradation of Aβ (**Table [1B](#T1B){ref-type="table"}**; [@B63]; [@B98]; [@B30]; [@B33]; [@B48]; [@B7]).

###### 

Proteases/enzymes involved in the cleavage of Aβ peptide.

  Protease/enzyme      Description
  -------------------- -----------------------------------------------------------------------------------------------------------------
  ACE                  Angiotensin-converting enzyme
  CatB                 Cathepsin B, a cysteine protease in lysosome
  CatD                 Cathepsin D, a cysteine protease in lysosome
  ECE                  Endothelin-converting enzyme
  FXIa                 Serine protease factor XIa
  Gelatinase A         Secreted endopeptidase
  IDE                  Insulin-degrading enzyme
  MMP-9                Matrix metalloproteinase
  NEP                  Neprilysin, neutral endopeptidases
  PreP                 Presequence protease
  The plasmin system   Components including plasmin and urokinase-type plasminogen activator (uPA), tissue plasminogen activator (tPA)
  α~2~M complex        Serine protease-α~2~ macroglobulin complex

Besides the proteolysis for Aβ degradation, receptor-mediated endocytosis of Aβ that delivers Aβ to lysosome for degradation also contributes to the clearance of toxic Aβ peptide and Aβ deposits. Low-density lipoprotein receptor-related protein 1(LRP1) is considered to be the vital modulator in this process by probably direct binding to Aβ for uptake ([@B67]) or through Aβ receptor such as heparin sulphate proteoglycan (HSPG; [@B55]) and GPI-anchored cellular prion protein (PrP^c^; [@B95]) to facilitate Aβ trafficking. In addition, Aβ aggregates may also undergo maropinocytosis or phagocytosis for clearance, of which the critical step about actin polymerization is regulated by LRP1([@B54]). Apolipoprotein E (ApoE), as a major ligand for LRP1 and an important partner of Aβ, plays dual roles in Aβ clearance ([@B66]; [@B54]). Moreover, induction of another degrading pathway of autophagy serves to accelerate the clearance of both soluble Aβ and Aβ aggregates ([@B83]).

Animal Models Related with A**β** for AD
========================================

Various types of animal models related to Aβ have been created to dissect the mechanisms for the development and progression of AD, the majority are overexpression transgenic lines (see the summary in **Table [1C](#T1C){ref-type="table"}**; [@B84]; [@B31]; [@B26]; [@B71]; [@B68]).

###### 

Summary for Aβ related transgenic animal models.

  Organism                   Aβ related transgenic strains             Description
  -------------------------- ----------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Caenorhabditis elegans*   *P~unc-54~::SP:: Aβ^1-42^*                β-amyloid constitutive formation in muscles
                             *P~myo-3~::SP:: Aβ^1-42^::long 3′UTR*     Inducible larval paralysis in muscles
                             *P~snb-1~::SP:: Aβ^1-42^::long 3′UTR*     Inducible β-amyloid expression in Pan-neurons
                             *P~eat-4~::SP:: Aβ^1-42^*                 β-amyloid formation in glutamatergic neurons
  *Drosophila*               *gmr-Gal4 \> UAS-BACE;UAS-dPsn;UAS-APP*   Aβ generated from APP that are cleaved by β-secretase and γ--secretase in retina
                             *elav-Gal4 \> UAS-Aβ~42~*                 Inducible Aβ~42~ expression in the brains
                             *gmr-Gal4 \> UAS-Aβ~42~*                  Inducible Aβ~42~ expression in the retina
                             *act5c-Gal4 \> UAS-Aβ~42~*                Inducible Aβ~42~ ubiquitous expression
  Mouse                      Tg2576                                    Aβ plaques as well as some vascular amyloid are induced by overexpression a mutant form of APP (APPK670/671L)
                             APP23                                     Excessive Aβ production induced by overexpression of mutant human APP carrying the Swedish mutation.
                             PDAPP                                     Expression of mutant human APP carrying the Swedish mutation under the PDGF promoter.
                             TgCRND8                                   Expression of human APP carrying the Swedish and Indiana mutations under the PrP promoter.
                             PS1M146V                                  Expression of human PS1(M146V) under the PDGF promoter.
                             APP/PS1                                   Excessive Aβ production induced by Overexpression of two mutant forms of APPSWE and PSEN1d E9
                             5xFAD                                     Double transgenic APP/PS1 mouse model with co-expression five AD mutations including APP Swedish,Florida and London mutations and PS1 M146L and L286V mutations.
  Rat                        TgAPPswe                                  Expression of hAPP751with the Swedish mutation driven by the PDGF promoter
                             UKUR28                                    Expression of hAPP751with the Swedish and Indiana mutations driven by the PDGF promoter
                             UKUR25                                    Expression of hAPP751with the Swedish and Indiana mutations as well as PS1(M146L) driven by the PDGF promoter
                             hAPP695                                   Expression of hAPP695 (wild type) driven by the UbiquitinC promoter
                             Tg6590                                    Expression of hAPP695 with the Swedish mutation driven by the UbiquitinC promoter
                             APP21APP31                                Expression of hAPP695 with the Swedish and Indiana mutations driven by the UbiquitinC promoter
                             PSAPP (Tg478/Tg1116/Tg11587)              Triple transgenic strain carrying expression of hAPP695 with the Swedish mutation under the Rat synapsin I promoter, hAPP695 with the Swedish and London mutations under the PDGFβ promoter and expression of human PS1(M146V) driven by the Rat synapsin I promoter.
                             TgF344-AD                                 Expression of hAPP695 with the Swedish mutation and PSΔE9 under the murine PrP promoter.
                             McGill-R-Thy1-APP                         Aβ accumulation induced by expression the human APP carrying both the Swedish and Indiana mutation under the control of the murine Thy 1.2 promoter.

Despite the existing innate disadvantages. e.g., the transgenic flies that express both human APP and β-secretase BACE1 displayed Aβ accumulation, the animal models are useful to screen genes involved in APP processing ([@B111]; [@B41]), making a great contribution to the development of this field. The secreted-Aβ model in *Drosophila* is a direct approach to investigate the toxicity caused by Aβ ([@B34]; [@B22]; [@B51]). The *Caenorhabditis elegans* Aβ-expressing models developed in different tissues are also helpful for examining genes involved in Aβ-induced toxicity ([@B69]; [@B107]). Phenotypes were also analyzed in zebrafish through high-throughout screen by treatment with Alzheimer's γ-secretase inhibitors to determine efficient compounds for blocking Aβ generation ([@B6]).

Aβ infusion models are that different species of Aβ peptides is directly injected in the rodent brains. They could mimic the most aspects of AD and deliver experimental results for analysis in a relatively short time ([@B80]; [@B44]; [@B81]). However, these approaches usually induce much higher levels of Aβ in the brains than that exists in the patients, and the results usually vary due to differences in methodology and the concentration of Aβ and the duration treatment. Although most of the models do not show Tau pathology and other shedding fragments from APP processing may also influence neuron systems, transgenic rodent models with overexpression of wild type or mutated human APP can recapitulate some features of AD pathology and provide great convenience to discover more regulators involved in the onset of AD ([@B21]; [@B1]; [@B65]; [@B87]). Nevertheless, no model system is impeccable, further understanding of the molecular mechanisms for Aβ-initiated AD pathology would still be desirable.

Overviews of Current Therapeutics Targeting A**β**
==================================================

According to the conventional approaches targeting Aβ, therapeutic strategies focus on reducing Aβ production via inhibition of β- and γ-secretases to prevent Aβ aggregation and facilitate Aβ clearance. However, the results are not so inspiring, as all the strategies have failed in clinical trials. Recently, immunotherapies by two monoclonal antibodies against Aβ have been tried. One is Bapineuzumab that could recognize both soluble and insoluble forms of Aβ; the other one is Solanezumab that targets Aβ central domain and recognizes only soluble Aβ. Yet both of them failed to improve the clinical outcomes in patients in phage III trials ([@B27],[@B28]; [@B89]), which suggests that targeting Aβ alone might not be enough to impede AD progression and multiple steps of Aβ modulations should be taken into consideration according to the different clinical phenotypes in AD patients. e.g., the activity of Foxp3+ regulatory T cells (Tregs) has been reported to be related with Aβ plaque clearance, suggesting novel immunosuppression curing way ([@B9]). Moreover, other approaches besides immunotherapy also need to be explored in order to understand multiple regulations of Aβ for the development of therapies for treating AD.

Conclusion and Perspectives
===========================

The vital role of Aβ as an initiator in the pathology of AD has been well accepted. Aβ production mainly depends on APP processing, whereas Aβ removal is largely associated with proteases and lysosomal enzymes. Subcellularlly, Aβ production together with Aβ precursor protein APP seems closely related with mitochondria, the major source of energy for the brain. Mitochondrial changes including increasing ROS production and reducing ATP generation are in an age-dependent manner. ROS-related oxidative stress induces more Aβ production, while Aβ and APP localized to mitochondrial membranes cause mitochondrial damage by elevating ROS production, blocking the transport of nuclear-encoded mitochondrial protein and disrupting ETC activities. However, the mechanisms of Aβ and APP transport into mitochondrial membranes are still unknown. Future work focus on this part might provide well understanding between mitochondria and APP as well as Aβ production, which might be helpful for exploring new compounds.

On the other hand, microglial cells play very important roles in the removal of accumulated Aβ not only by phagocytosis but also by releasing proteases such as IDE for degradation, and it is also associated with the innate immune system induced by the aggregated Aβ. Therefore, further researches are needed to find how to keep the clearance function of microglial cells without being impaired by the proinflammatory cytokines.

Although tremendous progress has been made in the development therapeutic strategies targeting Aβ, more work are still needed to find efficient drugs for curing AD. Network regulations of Aβ should be taken into consideration for the therapy approaches, and it would be instrumental to create good animal models and find more specific biomarkers for the Aβ-mediated pathogenesis of AD.
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